Home » Topics » BioWorld Science, Endocrine/metabolic

BioWorld Science, Endocrine/metabolic
RSS

Indevus reports positive results from phase III trial of Nebido for male hypogonadism

Jan. 24, 2008

KV Pharmaceutical acquires rights to Gestiva

Jan. 24, 2008

Recent patents disclose novel therapeutic agents for obesity

Jan. 24, 2008

Positive phase III preliminary results reported for prolonged-release octreotide

Jan. 23, 2008

Trophos completes enrollment of first 90 patients in phase IIa clinical trial of TRO-19622

Jan. 23, 2008

Diamyd reports 30-month results from phase IIb study of diabetes vaccine Diamyd

Jan. 23, 2008

VIRxSYS signs research agreement with National Heart, Lung, and Blood Institute

Jan. 23, 2008

Novel lysosomal enzyme replacement therapy for MPS that crosses the BBB

Jan. 23, 2008

Promising results for GW cannabinoid treatments for diabetes and metabolic disorders

Jan. 22, 2008

GSK will not option XL-784 for further development

Jan. 22, 2008

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for May 15, 2026.
ASGCT 2026: Circular RNA, the new beast in gene and cell therapy
BioWorld
Circular RNA (circRNA) is not a new concept, but it is a novel strategy in the field of gene and cell therapy. While mRNA vaccines have revolutionized medicine,...
ASGCT 2026: Uncovering the mechanisms of AAV toxicity
BioWorld
Gene therapies rely on vectors to reach the target tissue where they act, such as adeno-associated viruses (AAVs) or lipid nanoparticles (LNPs), among other...
Fosun secures rights to Aribio’s AR-1001 in potential $4.7B deal
BioWorld
Shanghai Fosun Pharmaceutical (Group) Co. Ltd. is paying $60 million up front for an option to secure exclusive rights to Aribio Co. Ltd.’s oral phase III-stage...
Biogen AD drug shows tau, cognition benefit, despite trial miss
BioWorld
Biogen Inc. has decided to advance diranersen (BIIB-080) into registrational trials for early Alzheimer’s disease, even though the antisense oligonucleotide...